Cargando…
Tumor PD-L1 status and CD8(+) tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
INTRODUCTION: The aim of this study was to evaluate the expression of PD-L1 in oropharyngeal squamous cell carcinoma. Its relation with clinicopathological variables, tumor infiltrating lymphocytes and survival was also determined. RESULTS: Positive PD-L1 status for the SP142 clone related with impr...
Autores principales: | De Meulenaere, Astrid, Vermassen, Tijl, Aspeslagh, Sandrine, Deron, Philippe, Duprez, Fréderic, Laukens, Debby, Van Dorpe, Jo, Ferdinande, Liesbeth, Rottey, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655210/ https://www.ncbi.nlm.nih.gov/pubmed/29113315 http://dx.doi.org/10.18632/oncotarget.19045 |
Ejemplares similares
-
Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022) -
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
por: De Meulenaere, Astrid, et al.
Publicado: (2021) -
Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?
por: Almangush, Alhadi, et al.
Publicado: (2022) -
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021) -
Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
por: Meireson, Annabel, et al.
Publicado: (2021)